8 Biotechnology Stocks to Sell Now

by Portfolio Grader | October 3, 2013 11:30 am

This week, the ratings of eight Biotechnology stocks on Portfolio Grader[1] are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Genomic Health, Inc.’s (NASDAQ:GHDX[2]) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock price stands at $30.33, on the rise for the past four days. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. The stock currently has a trailing PE Ratio of 771.30. For a full analysis of GHDX stock, visit Portfolio Grader[3].

The rating of Acorda Therapeutics, Inc. (NASDAQ:ACOR[4]) declines this week from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. Shares of the stock have been exchanging at an usually rapid pace, twice the rate of the week prior. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock[5].

Amarin Corporation Plc Sponsored ADR (NASDAQ:AMRN[6]) earns a D this week, moving down from last week’s grade of C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of Oct. 1, 2013, 14.5% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock[7].

Slipping from a C to a D rating, Durata Therapeutics, Inc. (NASDAQ:DRTX[8]) takes a hit this week. Durata Therapeutics focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The stock gets F’s in Earnings Revisions, Equity, and Cash Flow. For a full analysis of DRTX stock, visit Portfolio Grader[9].

Exelixis, Inc. (NASDAQ:EXEL[10]) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Oct. 1, 2013, 22.6% of outstanding Exelixis, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock[11].

Trius Therapeutics, Inc. (NASDAQ:TSRX[12]) gets weaker ratings this week as last week’s C drops to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader[13].

This is a rough week for Discovery Laboratories, Inc. (NASDAQ:DSCO[14]). The company’s rating falls to D from the previous week’s C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock[15].

The rating of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN[16]) slips from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of Oct. 1, 2013, 15.7% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. Trade volume is up 1167.1% from the previous week. For more information, get Portfolio Grader’s complete analysis of ACHN stock[17].

Louis Navellier’s proprietary Portfolio Grader[18] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[19].

Endnotes:
  1. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  2. GHDX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GHDX
  3. For a full analysis of GHDX stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GHDX
  4. ACOR: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACOR
  5. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACOR
  6. AMRN: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=AMRN
  7. For more information, get Portfolio Grader’s complete analysis of AMRN stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=AMRN
  8. DRTX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DRTX
  9. For a full analysis of DRTX stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DRTX
  10. EXEL: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=EXEL
  11. For more information, get Portfolio Grader’s complete analysis of EXEL stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=EXEL
  12. TSRX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=TSRX
  13. For a full analysis of TSRX stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=TSRX
  14. DSCO: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DSCO
  15. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=DSCO
  16. ACHN: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACHN
  17. For more information, get Portfolio Grader’s complete analysis of ACHN stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ACHN
  18. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  19. here: http://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: http://investorplace.com/2013/10/8-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-2/
Short URL: http://invstplc.com/1fuPE2B